WO1992018106A1 - Method of manufacturing solid dispersion - Google Patents
Method of manufacturing solid dispersion Download PDFInfo
- Publication number
- WO1992018106A1 WO1992018106A1 PCT/JP1992/000470 JP9200470W WO9218106A1 WO 1992018106 A1 WO1992018106 A1 WO 1992018106A1 JP 9200470 W JP9200470 W JP 9200470W WO 9218106 A1 WO9218106 A1 WO 9218106A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrochloride
- ray diffraction
- solid dispersion
- powder
- test
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Definitions
- the present invention translates into a method for producing a planar dispersion. More specifically, the present invention relates to a method for producing a solid dispersion using a twin-screw extruder, and can be mainly used in the field of pharmaceutical production.
- the term “hedron-body” refers to one of drug substance-containing drug substance powders in which a drug is dissolved or dispersed in a polymer carrier.
- Solid dispersions are very useful for increasing the solubility of a drug, controlling the release rate of a drug from a drug product, improving bioavailability, etc. The need is great.
- Conventional methods for producing a solid dispersion include a melting method in which a drug and a polymer carrier are heated and melted and then cooled, and a method in which the drug and the polymer carrier are dissolved in an appropriate solvent, There is a solvent method characterized by the removal of water, a melt-solvent method combining both features, and the like.
- the fusion method has a drawback that it is decomposed by heat or is likely to be decomposed or cannot be used for molecular support.
- the solvent method does not have the drawbacks of the above-described melting method, but has the following drawbacks because an organic solvent such as an alcohol-chlorine solvent is used.
- An object of the present invention is to establish a method for producing an excellent facet fraction overcoming the above-mentioned drawbacks inherent in the fusion method and the solvent method.
- the gist of the present invention resides in that a mixture of a drug, a polymer carrier, and the like, which are components of a facepiece, is treated with a two-glaze extruder.
- 2 tt type extruder is a type of front-discharge extrusion granulator characterized by having two screws, and is a single-shaft extruder having only one screw. It has a different structure from a truder.
- the 2-axis ETAS trusser is a metering machine, barrel (cylinder), screw, paddle, screw pot, barrel heating / cooling device, exit die (cooling die, heating die, molding die), It is a device that can change the pressing force and kneading temperature during the kneading process by changing the screen type, rotation speed, and the combination of the screw elements on the glaze.
- the barrel can be used in combination of length and type depending on the application, and temperature control is possible if necessary.
- twin-screw extruder requires only two screws. Material can be processed and the screw elements on the shaft can be rearranged, etc., so it has superior features that are incomparable to single-screw extruders, for example: .
- the screws do not interfere with each other, and the raw materials do not rotate together with the screws. Therefore, the characteristics of the processing raw materials are not so affected. Therefore, the 2 ⁇ type extruder can process even high oil content and long-lasting raw materials that cannot be processed by the 1 shaft type extruder.
- twin-screw extruder is superior to the 1tt-type etrus extruder in terms of shearing force, mixer, and transport capacity. Therefore, for example, when processing a protein, organization of the protein, which is not possible with a single-axis extruder, is possible with a two-axis extruder.
- the two-wheel extruder has a low frictional heat with the barrel, so it is easy to control the temperature. Therefore, the 2suke type extruder is advantageous for pharmaceuticals and the like that do not like commercial temperature.
- the macromolecular carrier used in the present invention is a natural or synthetic high molecular compound that can be generally used as a raw material for pharmaceutical preparations, and loses its function when discharged from the pores of the die of the biaxial Etastruder. There is no particular limitation as long as the substance is not used.
- Examples of such a ⁇ ⁇ molecular carrier include ⁇ -dependent polymer carriers, ⁇ independent ⁇ molecular carriers, and water-soluble polymer carriers, and examples thereof include the following polymer compounds.
- Hydroxypropyl methylcellulose phthalate 220824 ( ⁇ 50), hydroxyb D virmethylcell orifice 220731 ( ⁇ 55), Hydroxypropyl methylcellulose acetate succinate (A-coat), carboxymethylethylcellulose (CI BC), tungstic acid fluoric acid cell ⁇ -source (CAP), methacrylic acid cobolimer LD (L30D55) , Meta Ryo Co-Po Limer S (S-100), Amino Alkyl Meta!
- Rate copolymer E gastric solubility
- polybutylacetal getylaminobutyrate ABA
- polybulpyridone K-25, 30, 90; PVP
- ethylcellulose BC
- Meta-acrylic acid copolymer Polymer RS (RS 30D), polybutyl alcohol (PVA), methyl cellulose (MC), hydroxypropyl cellulose (HPC), hydroxymethyl bil methylcell ⁇ -source 2208 (metrose 90SH), Hydroxylab mouth virumethylcellulose 2906 (Methorose 65SH), Hydrodipsiprovir methylcelluose mouth 2910 ⁇ Methorose 60SH), carboxymethylcellulose sodium (sodium fiber glycolate sodium), Dexto Lin, burlan, arabia gum, tragacanth, sodium luginate, propylene glycol alginate, carten , Gelatin, 3 ⁇ 4 flour, pressurized E ⁇ , Li phospholipids (lecithin), Darko mannan like.
- Each of the above polymer carriers can be used alone, or two or more of them can be used as a mixture, if necessary.
- the size of the particle SE of the molecular ft should be a particle diameter that can be put into the machine body from the hopper of the twin-screw extruder. ⁇ It is below. Even larger particles of a polymer carrier can be used by coarse grinding in advance.
- Pressure, temperature, feed rate, water or plasticizer in the production method of the present invention The setting conditions such as the amount of added and the supply rate vary depending on the drug used, the molecular carrier, the type of biaxial extruder, and other conditions. It is important to combine them, and it is necessary to change them according to the desired product characteristics.
- the ratio of mixing the drug and the molecular carrier depends on the type, purpose, spreading properties, etc. of the drug and molecular carrier, but the ratio of the polymer carrier to the drug 1 is 0.1 to 999, preferably 0.1 to 999. 5 to 500, more preferably 1 to 50 is suitable.
- an aqueous solution or a separating solution of the plasticizer can be added before or during the application to the twin-screw type Etrusstruder.
- the degree of transition of the polymer carrier can be reduced, so that the molding temperature can be set below the decomposition temperature of the drug and the quotient molecular carrier, and the decomposition of the drug or polymer carrier by heat can be performed. Can be prevented.
- an aqueous solution or dispersion of a plasticizer can be similarly added to a system containing no heat-labile drug or polymer carrier.
- a plasticizer for lowering the transition temperature of the molecular carrier a compound or the like used as a plasticizer for a film coating agent in the pharmaceutical field can be used.
- the following compounds can be mentioned.
- Cetanol medium chain fatty acid triglyceride, polyoxyethylene—polyoxypropylene glycol (bull nick), macrogol (200, 300, 400, 600, 1000, 1500, 1540, 4000. 6000, 20000). Tritin-cetin, triethyl citrate (citroflex), etc.
- the plasticizer that can be used in the present invention is not limited to these, and any compound that has an effect of reducing the degree of tillering S of the polymer carrier can be used.
- the amount of the plasticizer to be added varies depending on the drug used, the quotient carrier, etc., but 1 to 80% is appropriate for the polymer carrier, and preferably 5 to 50% is quick. .
- the method of addition may be directly from the beginning to the mixture system of the polymer carrier and the drug, or may be one that is permanently dissolved or dispersed during molding. As described above, the method of adding the plastic is not particularly limited.
- the drug that can be used in the present invention is not particularly limited, but a drug that is stable to temperature, particularly a drug that does not decompose at 50T or less is preferable.
- examples of such drugs include the following.
- Dibrofilin Salbutamol triureate, Chlorbrenaline citrate, Formoterol fumarate, Orcibrenaline sulphate, Bilbuterol citrate, Hexobrenalin sulphate, Vitortel succinate, Sigma-cletol hydrochloride, Sulfuric acid hydrochloride, Sulfuric acid Terbutaline, mabuterol hydrochloride, pentoterol hydrobromide, methoxyphenamine hydrochloride.
- Bottle mouth brobranol hydrochloride ⁇ -yl, carteol hydrochloride, methotrolone tartrate, labetalol hydrochloride, oxourenol hydrochloride, acebutol hydrochloride, bufenrolol hydrochloride, alpreno hydrochloride Chinolol, oxalate chinolol, oxprenolol hydrochloride, nadolol.
- Bucumolol hydrochloride indenol hydrochloride, timolol maleate, difunolol hydrochloride, carteolol hydrochloride, bupranolol hydrochloride. 1 7.
- Antiarrhythmic agent ⁇ -yl, carteol hydrochloride, methotrolone tartrate, labetalol hydrochloride, oxourenol hydrochloride, acebutol hydrochloride, bufenrolo
- Feline toine sodium palproate, metal bital, rubbamazevin.
- N-phenylaminate maleate clemastine fumarate, mequitazine, alimemazine tartrate, butadiene cyclate.
- Vitamin Bl Vitamin B2, Vitamin B6, Vitamin B12, Vitamin, Vegetable acid.
- Enalapril maleate, alasepril, delapril hydrochloride Enalapril maleate, alasepril, delapril hydrochloride.
- the solid dispersion obtained according to the present invention can easily obtain solid dispersion particles having an arbitrary particle system by being crushed using an appropriate crusher, and is used as it is as a powder or granule. You can also.
- tablets, granules, fine granules, capsules, or capsules filled with a half-sided dispersion, capsules filled with an oily substance, or the like can be prepared using the pulverized fine particles. It can also be used as a mouth preparation.
- the technology described in the above-mentioned document is a technology that applies a 1 ⁇ -type extruder, which is extremely inferior to a 2-axis extruder, as described above. It is different from the solid dispersion produced. Further, the above-mentioned technology is intended to produce a sustained-release agent, and the greed and sustained-release agent is produced at a high temperature.
- the above technique is different from the present invention, which is a method for producing a face dispersion, which overcomes the disadvantages of the melting method and the solvent method, and has different objects, configurations, and effects.
- a solid dispersion can be obtained without placing a drug and a polymer carrier in a high temperature state and without using any organic solvent.
- a facepiece dispersion body can be formed and taken out independently, and a facepiece dispersion having an arbitrary size or an arbitrary shape can be manufactured by changing the discharge hole diameter ⁇ of the die. .
- Example 1 Compound A (Compound name; Methyl 2,6-dimethyl-14- (2-2-trifluorophenyl) -1-5- (2-oxo-1,3,2-Dioxaphosphorinan-2-yl) 1-1,4-Dihydro 500 g of powdered powder (average particle size: 60 jm) containing powdered viridine-3-carboxylate (hereinafter the same applies) is added to hydroxy ⁇ -hydroxypropyl methylcellulose acetate acetate (trade name: ⁇ Coat) , AS-MP, manufactured by Shin-Etsu Chemical Co., Ltd. The same applies hereinafter.
- This compact is finely pulverized using a sample mill (type: AP-S, manufactured by Hosokawa Iron Works, the same applies hereinafter), and the obtained fine particles are eluted with a test sample (65 to 100 mesh), powder X-rays. Samples were used for diffraction (250 mesh through) and solubility measurement (65 to 100 mesh).
- 500 g of indomethacin was mixed with 2500 g of virmethylcellulose phthalate (trade name; HPMCP, HP-55P grade, manufactured by Shin-Etsu Chemical Co., Ltd .; the same applies hereinafter) to 500 g of indomethacin. While adding a 50% (w / w) aqueous solution of reticle, the molded product was formed by a biaxial extruder equipped with a 4 ⁇ 0X2 die at a barrel temperature of 80t and an extrusion speed of 200rpm. (Solid dispersion) was obtained.
- the compact was pulverized using a sample mill, and the obtained fine particles were used as samples for a dissolution test, powder X-ray diffraction, and solubility measurement.
- Example 3 After mixing 1500 g of indomethacin with 1500 g of polyvinyl terephthalic acid acetyl acetate (trade name; AEA, manufactured by Sankyo Pharmaceutical Co., Ltd.), 50% (w / «) of triacetin was dispersed.
- the barrel temperature was set to 90 'using a twin-screw extruder equipped with a die with a mouth ⁇ X2 while adding the elongate, and the molding process was performed at an extrusion speed of 200 rpn to form a molded body (plane dispersion). Obtained.
- Compound B (Compound name: 4-Jetyl Rmino 1,1-Dimethyl-2-butynyl (Earth) 1-Cyclohexyl or -Phenyldalilate hydrate mouth chloride Monohydrate) 200 g of methacrylic acid Copolymer LD (trade name: Eudragit, Grade; L30D55, Publisher: Kokushokai Co., Ltd.) After mixing 1600 g of wheat starch and 200 g of wheat starch, a die with a diameter of 4 ⁇ 0 X 2 was added while adding (adding) water. The barrel temperature was set to 100 t using a two-mould extruder equipped with, and molding was performed at an extrusion speed of 200 rpoi to obtain a molded body (plane dispersion).
- the barrel temperature was adjusted to 100 t using a twin-screw extruder equipped with a 4 ram 0 X 2 die while adding water.
- the molding was performed at a set extrusion speed of 200 rpro to obtain a molded body (plane body separated body).
- the compact is finely pulverized using a sample mill, and the obtained particles are subjected to a dissolution test (65 to 100 mesh), powder X-ray diffraction (pass through 250 mesh), and a solubility measurement (65 to 100 mesh).
- the barrel temperature was adjusted using a twin-screw extruder equipped with a die of 2 mn 0 x 3 while adding water.
- the molding process was performed at an extrusion speed of 200 ° to obtain a molded product (solid decomposed material).
- the molded product is pulverized vigorously using a sample mill, and the obtained fine particles are subjected to a dissolution test (65 to 100 mesh), powder X bran diffraction (pass through 250 mesh), and a solubility measurement (65 to 100 mesh). ).
- the molded body is finely pulverized using a sample mill, and the obtained fine particles are subjected to a dissolution test (65 to 100 mesh), powder X-ray diffraction (250 mesh pass), and solubility measurement (65 to 100 mesh). Sample.
- the compact was finely pulverized using a sample mill, and the obtained fine particles were used as samples for a dissolution test (65 to 100 mesh) and a powder X-ray diffraction (250 mesh pass).
- Example 1 Extruder-treated product
- Comparative Example 1 the JP Pharmaceutical No. 1 solution (PH1.2), the sample solution 900 nl, the paddle method, Under the conditions of ⁇ , no elution of Compound A was observed as shown by HI.
- rapid elution was observed with the Japanese Pharmacopoeia second solution (PH6.8), test solution 900oil, paddle method, and lOOrpn.
- Example 1 and Comparative Example X-ray powder diffraction of the compact produced in Example 1 resulted in the crystal peak of Compound A observed in the raw powder and in the physical mixture of equal mixing ratio as shown in Figure 2. Had disappeared.
- Table 1 shows the results of measuring the solubility of the test sample prepared in Example 1. As shown in Fig. 1, the solubility was increased about 4 times as compared with the bulk powder. This solubility was almost similar to the solid dispersion prepared by the solvent method of Comparative Example 1. table 1
- Example 5 Weigh indomethacin 35iw equivalent of the test sample obtained in Example 5 and pour it into 900 nl of JP First Solution (PHI. 2), and perform the elution test under the conditions of paddle method and lOOrpnu measurement wavelength of 320 ⁇ >. Carried out. As a result, as shown in FIG. 5, it was confirmed that the release of indomethacin was suppressed, and the release rate was increased as compared with the amount of wheat flour added.
- PHI. 2 JP First Solution
- FIG. 1 shows the results of elution of the isomers. From the start of the test to 180 minutes after the start of the test, the elution results of the first JP (PH1.2) were used. From 180 minutes after the start of the test, the dissolution and narrow results of the Japanese second solution (PH6.8) were obtained. Shown. The horizontal axis represents time (minutes), and the vertical axis represents the dissolution rate (%) of compound A, respectively. In the figure, Hata indicates the elution curve of the solid component obtained in Example 1, and ⁇ indicates the elution curve of the solid component obtained in Comparative Example 1.
- FIG. 2 shows the results of powder X-ray diffraction of a compound A-containing face dispersion.
- the top X-ray diffraction pattern shows the X-ray diffraction result of the solid dispersion obtained in Example 1, and the X-ray diffraction pattern at the second * from the top shows the solid dispersion obtained in Comparative Example 1.
- X »From the diffraction results the third X-ray diffraction from the top 0 shows that the ratio of compound A to hydroxymethyl virmethylcell ⁇ -succinate succinate (A coat, AS-MP grade) is 1: 5 (compound A: The A-coat, the same ratio as in Example 1 and Comparative Example 1).
- the X-ray diffraction result of the physical mixture is as follows. Shown respectively. The horizontal axis represents the diffraction angle (2 ⁇ ), and the vertical axis represents the diffraction intensity (CPS).
- FIG. 3 shows the results of a dissolution test of the solid dispersion obtained from Example 2 obtained in Example 2.
- the horizontal axis is the time (minutes), and the vertical axis is the The dissolution rate (%) is shown.
- FIG. 4 shows the results of powder X-ray diffraction of a solid dispersion containing indomethacin and the like.
- the top X-ray diffraction pattern shows the results of X-ray diffraction of the solid dispersion obtained in Example 2, and the second X-ray diffraction pattern from the top shows indomethacin and hydroxymethyl bil methylcell monophthalate.
- the third X-ray diffraction E shows the X-ray diffraction result of a physical mixture in which the ratio of indomethacin to HPMCP is 1: 5 (indomethacin: HPMCP, the same ratio as in Example 2).
- Diffraction H shows the results of X-ray diffraction of bulk indomethacin powder.
- the «axis indicates the diffraction angle (2), and the slow axis indicates the diffraction intensity (CPS).
- FIG. 5 shows the results of a dissolution test of the indomethacin-shape-planed solid dispersion obtained in Example 5 in the Japanese Pharmacopoeia First Solution (PH1.2).
- the horizontal pot represents the hour K (minutes), and the vertical port represents the elution rate (%) of indomethacin.
- the graph shows the elution curve of the solid dispersion obtained by adding 300 g of wheat flour in Example 5, and the graph shows the elution of the planar dispersion obtained by adding 500 g of wheat flour in Example 5.
- ⁇ represents the elution curve of the solid dispersion obtained by adding 1000 g of wheat »flour in Example 5, respectively.
- FIG. 6 shows the dissolution test results of Nif X divin-containing face dispersion ft obtained in Example 6 and Comparative Example 2.
- the horizontal axis represents time (minutes), and the vertical tt represents the dissolution rate (%) of diphediobin.
- FIG. 1 Shows the results of powder X-ray diffraction of Nifuedibin-Shain-I dispersion.
- the top X-ray diffraction pattern is the X-ray of the solid dispersion obtained in Example 6.
- the X-ray diffraction pattern at the second * from the top is the X-ray diffraction pattern of the solid dispersion obtained in Comparative Example 2.
- the X-ray diffraction pattern at the third from the top is Nifdibin and hydroxypropyl methylcellulose.
- the ratio of acetate succinates (A-coat, AS-P grade) is 1: 5 (diphenyl: A-coat, the same ratio as in Example 6 and Comparative Example 2).
- the X-ray diffraction results are shown, and the X-ray diffraction diagram at the bottom shows the X-ray diffraction results of the raw powder of ufuzivin.
- the horizontal axis represents the diffraction angle (2 ⁇ ), and the gentle axis represents the diffraction intensity (CPS).
- FIG. 8 shows the dissolution test results of the solid oxypeptinin halite obtained in Example 7 and Comparative Example 3.
- the horizontal axis represents time (minutes), and the vertical axis represents the dissolution rate (%) of oxybutun chanate.
- FIG. 9 shows the results of X-ray powder diffraction of a solid dispersion containing oxyptinin-supported acid and the like.
- the top-level X-ray diffraction H is the X-ray diffraction result of the planar solid obtained in Example 7, and the X-ray diffraction at the second * from the top is the X-ray diffraction of the solid sample obtained in Comparative Example 3.
- the X-ray diffractogram of the third test from the top shows that the ratio of oxyptinin hydrochloride to hydroxymethyl mouth virmethylcellulose acetate succinate (A coat, AS-MP grade) is 1: 5 (oxyptinin hydrochloride: X-ray diffraction results of the physical mixture (A coat, Example 7 and Comparative Example 3) are shown, and the X-ray diffraction diagram at the bottom shows the X-ray diffraction results of the raw powder of oxypeptinine hydrochloride.
- the horizontal axis represents the diffraction angle (2 ⁇ ), and the vertical axis represents the diffraction intensity (CPS).
- FIG. 10 shows the dissolution test results of the solid dispersions of dicardipine hydrochloride obtained in Example 8 and Comparative Example 4.
- the horizontal axis represents time M (minutes), and the vertical axis represents the dissolution rate (%) of dicardivine hydrochloride.
- FIG. 11 shows the results of powder X-ray diffraction of a solid dispersion of dicardipine hydrochloride. 3 ⁇ 4The top X-ray diffraction pattern shows the X-ray diffraction result of the solid dispersion obtained in Example 8, and the second X-ray diffraction pattern from the top shows the X-ray diffraction result of the solid dispersion obtained in Comparative Example 4.
- the third X-ray diffractogram from the top shows that the ratio of dicardibin hydrochloride to hydroxymethyl mouth vir methylcellulose phthalate (HPMCP, HP-55P grade) is 1: 5 (dicardibin dibasic acid: HPMCP, Example 8). And the same ratio as in Comparative Example 4), the X-ray diffraction result of the physical mixture, and the X-ray diffraction diagram at the bottom represent the X »diffraction result of the raw powder of dicardivin hydrochloride.
- the horizontal tt indicates the diffraction angle (2), and the potter indicates the diffraction intensity (CPS).
- FIG. 12 shows the results of a dissolution test of the solid dispersions of dichroknack nutshell obtained in Example 9 and Comparative Example 5. Indignation tt indicates time (minutes), and ⁇ ⁇ indicates the elution rate (%) of dichroknack nutrium.
- FIG. 13 shows the results of powder X-ray diffraction of a dispersion of a dihedral napkin-containing cuboid.
- the top X-ray diffraction pattern is the X-ray diffraction result of the solid dispersion obtained in Example 9, and the second X-ray diffraction pattern from the top is the X-ray diffraction result of the planar dispersion obtained in Comparative Example 5.
- the third X-ray diffraction diagram from the top shows that the ratio of Zinc ⁇ -F x NacNa and Hydroxyb mouth bil methylcellulose phthalate (HPMCP, HP-55P grade) is 1: 5 (Diclonapnax (The same ratio as that of HPMCP in Example 9 and Comparative Example 5).
- the X-ray diffraction result of the physical mixture is as follows. Shown respectively. The horizontal bow indicates the diffraction angle (2), and the Sui axis indicates the diffraction intensity (CPS).
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69222847T DE69222847T3 (de) | 1991-04-16 | 1992-04-14 | Verfahren zur herstellung einer festen dispersion |
CA002108575A CA2108575C (en) | 1991-04-16 | 1992-04-14 | Method of manufacturing solid dispersion |
EP92907654A EP0580860B2 (en) | 1991-04-16 | 1992-04-14 | Method of manufacturing solid dispersion |
DK92907654T DK0580860T4 (da) | 1991-04-16 | 1992-04-14 | Fremgangsmåde til fremstilling af en fast dispersion |
KR1019930703143A KR0182801B1 (ko) | 1991-04-16 | 1992-04-14 | 고체 분산체의 제조방법 |
US08/129,133 US5456923A (en) | 1991-04-16 | 1993-12-23 | Method of manufacturing solid dispersion |
GR980400035T GR3025864T3 (en) | 1991-04-16 | 1998-01-08 | Method of manufacturing solid dispersion |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11255491 | 1991-04-16 | ||
JP3/112554 | 1991-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992018106A1 true WO1992018106A1 (en) | 1992-10-29 |
Family
ID=14589572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1992/000470 WO1992018106A1 (en) | 1991-04-16 | 1992-04-14 | Method of manufacturing solid dispersion |
Country Status (12)
Country | Link |
---|---|
US (1) | US5456923A (ja) |
EP (1) | EP0580860B2 (ja) |
JP (1) | JP2527107B2 (ja) |
KR (1) | KR0182801B1 (ja) |
AT (1) | ATE159426T1 (ja) |
AU (1) | AU1537292A (ja) |
CA (1) | CA2108575C (ja) |
DE (1) | DE69222847T3 (ja) |
DK (1) | DK0580860T4 (ja) |
ES (1) | ES2111065T5 (ja) |
GR (1) | GR3025864T3 (ja) |
WO (1) | WO1992018106A1 (ja) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995005809A1 (fr) * | 1993-08-20 | 1995-03-02 | Nippon Shinyaku Co., Ltd. | Preparation restant dans l'estomac, forme moulee gonflee, et procede de preparation |
EP0642786A1 (en) * | 1993-09-14 | 1995-03-15 | Euro-Celtique S.A. | Method for the manufacture of a laxative composition |
EP0665009A4 (en) * | 1992-10-14 | 1996-02-28 | Nippon Shinyaku Co Ltd | PROCESS FOR DISLOCATION OF A CRYSTALLINE STATE. |
EP0665010A4 (en) * | 1992-10-16 | 1996-02-28 | Nippon Shinyaku Co Ltd | METHOD FOR PRODUCING WAX MATRICES. |
EP0729748A4 (en) * | 1993-11-18 | 1997-09-10 | Nippon Shinyaku Co Ltd | METHOD FOR PRODUCING STABLE MEDICINAL PRODUCTS AND PHARMACEUTICAL PREPARATION |
JP2000281561A (ja) * | 1999-03-26 | 2000-10-10 | Ajinomoto Co Inc | 新規溶媒法固体分散体製剤 |
US6139872A (en) * | 1996-08-14 | 2000-10-31 | Henkel Corporation | Method of producing a vitamin product |
US6462093B1 (en) | 1995-08-11 | 2002-10-08 | Nissan Chemical Industries, Ltd. | Method for converting sparingly water-soluble medical substance to amorphous state |
JP2003522097A (ja) * | 1998-02-16 | 2003-07-22 | フイズ インターナショナル リミテッド | 可溶化デリバリーシステムおよび製造方法 |
JP2004505911A (ja) * | 2000-08-03 | 2004-02-26 | ファイザー・プロダクツ・インク | コレステリルエステル転移蛋白質阻害薬の医薬用組成物 |
JP2005523895A (ja) * | 2002-02-01 | 2005-08-11 | ファイザー・プロダクツ・インク | コレステリルエステル輸送タンパク質阻害剤の固体非晶質分散物を含む医薬組成物 |
WO2009038112A1 (ja) * | 2007-09-21 | 2009-03-26 | Shionogi & Co., Ltd. | Npyy5受容体拮抗剤を含有する固形製剤 |
JP2009529516A (ja) * | 2006-03-10 | 2009-08-20 | アボット ゲーエムベーハー ウント コンパニー カーゲー | 活性成分の固体分散体を生産するためのプロセス |
JP4997683B2 (ja) * | 2000-09-25 | 2012-08-08 | 日本新薬株式会社 | 医薬固体分散体の製法 |
WO2014073889A1 (en) * | 2012-11-07 | 2014-05-15 | Sk Biopharmaceuticals Co., Ltd. | Solid dispersions of insoluble drug and preparation method thereof |
US9669047B2 (en) | 2012-12-27 | 2017-06-06 | Kao Corporation | Method for producing polyphenol composition |
US10894058B2 (en) | 2014-08-29 | 2021-01-19 | Kao Corporation | Method for producing solid dispersion containing hardly soluble polyphenol |
JP7082067B2 (ja) | 2016-05-13 | 2022-06-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 溶融押出用途のためのポリマーの粒子サイズおよび分布 |
Families Citing this family (256)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
DK0617612T3 (da) | 1991-12-18 | 1998-04-14 | Warner Lambert Co | Fremgangsmåde til fremstilling af en fast dispersion |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5811547A (en) * | 1992-10-14 | 1998-09-22 | Nippon Shinyaju Co., Ltd. | Method for inducing crystalline state transition in medicinal substance |
US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
IL110014A (en) | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
DE19509807A1 (de) * | 1995-03-21 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen |
GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US20020006438A1 (en) * | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
ATE251896T1 (de) * | 1994-12-19 | 2003-11-15 | Daiichi Seiyaku Co | Granulat-präparate mit kontinuierlicher freisetzung und verfahren zur herstellung |
BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
WO1997004782A1 (fr) * | 1995-07-26 | 1997-02-13 | Kyowa Hakko Kogyo Co., Ltd. | Dispersion solide ou preparation a dispersion solide de derives xanthine |
NZ330739A (en) * | 1996-05-20 | 1999-06-29 | Janssen Pharmaceutica Nv | Particulate solid dispersion of itraconazole and a water soluble polymer |
JPH10114682A (ja) * | 1996-10-11 | 1998-05-06 | Shimizu Kagaku Kk | グルコマンナン配合持効性内服用薬剤 |
US5955475A (en) * | 1997-06-30 | 1999-09-21 | Endo Pharmaceuticals Inc. | Process for manufacturing paroxetine solid dispersions |
DK0901786T3 (da) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
EP1741424B1 (en) | 1997-08-11 | 2018-10-03 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailabilty |
HN1998000115A (es) * | 1997-08-21 | 1999-06-02 | Warner Lambert Co | Formas de dosificación farmacéuticas sólidas |
US6013280A (en) * | 1997-10-07 | 2000-01-11 | Fuisz Technologies Ltd. | Immediate release dosage forms containing microspheres |
AU8621398A (en) * | 1998-01-12 | 1999-07-26 | Buhler Ag | Method and device for capsulating active ingredients |
KR100613706B1 (ko) * | 1998-05-27 | 2006-08-21 | 유로-셀띠끄 소시에떼 아노님 | 항염증용 제제, 특히 귀 및/또는 상부호흡기의 창상치료촉진용 약제 및/또는 소독 약제 |
DE19842914A1 (de) * | 1998-09-18 | 2000-03-23 | Basf Ag | Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon |
DE19842753A1 (de) | 1998-09-18 | 2000-03-23 | Bayer Ag | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
US6350786B1 (en) † | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
US6455526B1 (en) | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
WO2000035423A1 (en) * | 1998-12-16 | 2000-06-22 | Aventis Pharmaceuticals Inc. | Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
ES2306646T3 (es) * | 1999-02-09 | 2008-11-16 | Pfizer Products Inc. | Composiciones de farmacos basicos con biodisponibilidad incrementada. |
ES2307482T3 (es) * | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
DE19918325A1 (de) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
US7297344B1 (en) | 1999-05-27 | 2007-11-20 | Euro-Celtique, S.A. | Preparations for the promotion of wound healing in the upper respiratory tract and/or ear |
AU772314B2 (en) | 1999-05-27 | 2004-04-22 | Euro-Celtique S.A. | Preparations for the application of anti-inflammatory agents |
US7300667B1 (en) | 1999-05-27 | 2007-11-27 | Euro-Celtique, S.A. | Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract |
DE19945982A1 (de) * | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
DE19949897A1 (de) * | 1999-10-15 | 2001-04-19 | Rainer Rogasch | Formkörper und Verfahren zu dessen Herstellung |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
NZ529928A (en) | 1999-10-29 | 2005-10-28 | Euro Celtique Sa | Controlled release hydrocodone formulations |
JP5767429B2 (ja) | 1999-11-12 | 2015-08-19 | アッヴィ・インコーポレイテッド | 固体分散剤中の結晶化阻害剤 |
US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
JP2003518485A (ja) * | 1999-12-23 | 2003-06-10 | ファイザー・プロダクツ・インク | 向上された薬物濃度を与える医薬組成物 |
CA2403380A1 (en) * | 2000-03-21 | 2002-09-19 | Nippon Shinyaku Co., Ltd. | Sustained release oral preparations |
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
DE10031044A1 (de) | 2000-06-26 | 2002-01-03 | Bayer Ag | Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere |
EP1302201A4 (en) * | 2000-07-17 | 2007-09-05 | Astellas Pharma Inc | PHARMACEUTICAL COMPOSITION WITH IMPROVED ABSORBABILITY |
KR101045144B1 (ko) | 2000-10-30 | 2011-06-30 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
ITMI20010141A1 (it) * | 2001-01-26 | 2002-07-26 | Giuliani Spa | Procedimento per la preparazione di composizioni farmaceutiche o dietetiche per la veicolazione nell'intestino di sostanze labili |
CA2439366A1 (en) * | 2001-02-27 | 2002-09-06 | Julie Cahill | Pharmaceutical formulation comprising bicalutamide |
GB0104752D0 (en) * | 2001-02-27 | 2001-04-18 | Astrazeneca Ab | Pharmaceutical compositions |
US6465014B1 (en) * | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
UA81224C2 (uk) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
EP1401399A2 (en) * | 2001-06-22 | 2004-03-31 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
MXPA03011933A (es) | 2001-06-22 | 2004-03-26 | Pfizer Prod Inc | Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados. |
JP2004534812A (ja) | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | 薬物および中性ポリマーの分散物の医薬組成物 |
EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
AU2002304387A1 (en) * | 2001-06-22 | 2003-01-08 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
SE0103424D0 (sv) * | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
US7491407B2 (en) * | 2001-10-31 | 2009-02-17 | North Carolina State University | Fiber-based nano drug delivery systems (NDDS) |
IL162870A0 (en) | 2002-02-01 | 2005-11-20 | Pfizer Prod Inc | Controlled release pharmaceutical dosage forms of a cholesteryl estertransfer protein inhibitor |
MXPA04007433A (es) | 2002-02-01 | 2004-10-11 | Pfizer Prod Inc | Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado. |
EP1920766B1 (en) | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
US20030204180A1 (en) * | 2002-04-30 | 2003-10-30 | Kimberly-Clark Worldwide, Inc. | Temperature responsive delivery systems |
DE60329188D1 (de) | 2002-08-12 | 2009-10-22 | Bend Res Inc | Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren |
AU2003283769A1 (en) | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
US7423004B2 (en) * | 2003-01-31 | 2008-09-09 | Smithkline Beecham Corporation | Solid dispersion compositions |
CA2509958A1 (en) * | 2003-02-03 | 2004-08-19 | Novartis Ag | Pharmaceutical formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
KR20060096076A (ko) * | 2003-11-14 | 2006-09-05 | 화이자 프로덕츠 인크. | 비만 치료를 위한 mtp 저해제의 고형 무정형 분산물 |
JP2007513937A (ja) * | 2003-12-09 | 2007-05-31 | ファイザー インコーポレイテッド | Hivプロテアーゼ阻害剤を含む組成物 |
CA2555133A1 (en) | 2004-02-04 | 2005-09-01 | Pfizer Products Inc. | Substituted quinoline compounds |
US20050238721A1 (en) * | 2004-04-07 | 2005-10-27 | Acquarulo Lawrence A Jr | One step compounding extrusion of drug filled polymers |
JP2007536299A (ja) * | 2004-05-04 | 2007-12-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ltb4アンタゴニトを含有する固形医薬形態 |
CA2568056A1 (en) | 2004-05-25 | 2005-12-08 | Pfizer Products Inc. | Tetraazabenzo[e]azulene derivatives and analogs thereof |
MXPA06013891A (es) * | 2004-05-28 | 2007-01-26 | Pfizer Prod Inc | Composiciones farmaceuticas con comportamiento potenciado. |
MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
EP1848430B1 (en) * | 2004-12-31 | 2017-08-02 | Dr. Reddy's Laboratories Ltd. | Novel benzylamine derivatives as cetp inhibitors |
EP1844078B1 (en) | 2005-02-03 | 2016-09-28 | Bend Research, Inc | Pharmaceutical compositions with enhanced performance |
EP1690528A1 (de) * | 2005-02-11 | 2006-08-16 | Abbott GmbH & Co. KG | Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs |
BRPI0614197B8 (pt) * | 2005-08-02 | 2021-05-25 | Drossapharm Ag | composição farmaceuticamente eficaz em uma forma farmacêutica para administração peroral contendo pelo menos um dos ingredientes ativos indometacina e acemetacina, formas de administração, e, uso da composição |
US8187639B2 (en) * | 2005-09-27 | 2012-05-29 | Tissue Tech, Inc. | Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment |
ES2713062T3 (es) | 2005-09-27 | 2019-05-17 | Tissuetech Inc | Preparaciones de membrana amniótica y composiciones purificadas y métodos de uso |
EA017290B1 (ru) | 2005-11-28 | 2012-11-30 | Домейн Раша Инвестментс Лимитед | Композиции на основе ганаксолона |
US20080090897A1 (en) | 2006-08-11 | 2008-04-17 | The Johns Hopkins University | Compositions and methods for neuroprotectin |
EP2081435B1 (en) | 2006-09-22 | 2016-05-04 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
US7607596B1 (en) | 2007-03-07 | 2009-10-27 | Exxpharma, LLC | Process for enhancing the solubility of poorly soluble drugs |
WO2008135855A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer |
WO2008135828A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
US8974827B2 (en) | 2007-06-04 | 2015-03-10 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
US9545384B2 (en) | 2007-06-04 | 2017-01-17 | Bend Research, Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate |
US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
BRPI0814294A2 (pt) * | 2007-07-19 | 2015-02-03 | Metabolex Inc | Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas. |
EP2187968A4 (en) | 2007-08-21 | 2013-02-20 | Univ Texas | THERMOKINETIC MIXING FOR PHARMACEUTICAL APPLICATIONS |
CA2699157A1 (en) | 2007-09-10 | 2009-03-19 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
AU2008303129B2 (en) * | 2007-09-25 | 2013-08-01 | Formulex Pharma Innovations Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
FR2922100B1 (fr) * | 2007-10-11 | 2009-12-11 | Oreal | Procede de preparation de particules semi-solides a interet cosmetique |
WO2009053635A1 (fr) * | 2007-10-11 | 2009-04-30 | L'oreal | Composition cosmetique structuree |
US9233078B2 (en) | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
WO2009073215A1 (en) | 2007-12-06 | 2009-06-11 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
US20090163561A1 (en) * | 2007-12-21 | 2009-06-25 | Url Pharma, Inc. | Amorphous metaxalone and amorphous dispersions thereof |
US20100048912A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
PL2280704T3 (pl) * | 2008-03-31 | 2015-10-30 | Cymabay Therapeutics Inc | Związki oksymetylenoarylowe i ich zastosowania |
MX2011002149A (es) | 2008-08-27 | 2011-04-05 | Calcimedica Inc | Compuestos que modulan el calcio intracelular. |
US20110160222A1 (en) * | 2008-11-26 | 2011-06-30 | Metabolex, Inc. | Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
WO2010067233A1 (en) | 2008-12-08 | 2010-06-17 | Pfizer Inc. | 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir) |
US20110312916A1 (en) | 2009-02-05 | 2011-12-22 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
CR20170089A (es) | 2009-04-03 | 2017-07-17 | Plexxikon Inc | Composiciones del acido propano-1--sulfonico {3-[5-(4-cloro-fenil)-1h-pirrolo [2,3-b] piridina-3-carbonil] -2,4-difluoro-fenil}-amida y el uso de las mismas |
ES2559029T3 (es) | 2009-04-24 | 2016-02-10 | Tissue Tech, Inc. | Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas |
AU2010260208B2 (en) | 2009-06-16 | 2014-11-13 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Dosage forms of apixaban |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
ES2497566T3 (es) | 2009-10-01 | 2014-09-23 | Cymabay Therapeutics, Inc. | Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida |
US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
NZ599866A (en) | 2009-11-06 | 2014-09-26 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
JP5749790B2 (ja) * | 2010-03-26 | 2015-07-15 | ダウ グローバル テクノロジーズ エルエルシー | 多層溶融押出フィルム |
BR112012018818A2 (pt) * | 2010-03-26 | 2016-04-12 | Dow Global Technologies Llc | processo para produzir um filme extrudado de fundido e filme de extrudado de fundido |
CN102892815B (zh) * | 2010-03-26 | 2016-05-18 | 陶氏环球技术有限责任公司 | 熔体挤出的膜 |
EP2558866B1 (en) | 2010-04-15 | 2016-08-17 | Tracon Pharmaceuticals, Inc. | Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
AU2011248579A1 (en) | 2010-04-27 | 2012-11-29 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
WO2011139489A2 (en) | 2010-04-27 | 2011-11-10 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
US20130072519A1 (en) | 2010-05-21 | 2013-03-21 | Edward Lee Conn | 2-phenyl benzoylamides |
WO2011153514A2 (en) | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
WO2011163090A1 (en) | 2010-06-23 | 2011-12-29 | Metabolex, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
CA2803377C (en) | 2010-07-02 | 2018-03-20 | The Procter & Gamble Company | Methods of delivering a health care active by administering personal health care articles comprising a filament |
US9079891B2 (en) | 2010-08-27 | 2015-07-14 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
MA34948B1 (fr) | 2011-02-07 | 2014-03-01 | Plexxikon Inc | Composes et procedes de modulation de kinase, et leurs indications |
KR20140006879A (ko) | 2011-02-17 | 2014-01-16 | 에프. 호프만-라 로슈 아게 | 고온 용융 압출에 의해 활성 약학 성분을 과냉된 액체 상태로부터 제어되는 방식으로 결정화시키는 방법 |
TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
DE102011015370A1 (de) * | 2011-03-29 | 2012-10-04 | Emodys Gmbh | Matrix für eine orale Darreichungsform, Verfahren zu deren Herstellung sowie Verwendung derselben |
US9526770B2 (en) | 2011-04-28 | 2016-12-27 | Tissuetech, Inc. | Methods of modulating bone remodeling |
US9682044B2 (en) | 2011-06-10 | 2017-06-20 | Tissuetech, Inc. | Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof |
MX2014001849A (es) | 2011-08-18 | 2014-10-24 | Reddys Lab Ltd Dr | Compuestos de amina heterociclicos sustituidos como inhibidores de proteina de transferencia de ester colesterilo (cetp). |
SG2014014419A (en) | 2011-09-13 | 2014-07-30 | Pharmacyclics Inc | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
CN103958511A (zh) | 2011-09-27 | 2014-07-30 | 雷迪博士实验室有限公司 | 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物 |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
PT2800565T (pt) | 2012-01-06 | 2020-04-29 | Scripps Research Inst | Compostos de carbamato e processos para a sua preparação e utilização |
IN2012DE00674A (ja) | 2012-03-07 | 2015-08-21 | Nat Inst Of Pharmaceutical Education And Res Niper | |
MA37385B1 (fr) | 2012-04-06 | 2019-09-30 | Pfizer Inc Etat De Delaware | Inhibiteurs de diacylglycérol-acyltransférase 2 |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
NZ702548A (en) | 2012-06-04 | 2015-11-27 | Pharmacyclics Llc | Crystalline forms of a bruton’s tyrosine kinase inhibitor |
JP2015528001A (ja) | 2012-07-11 | 2015-09-24 | ティッシュテック,インク. | Hc−ha/ptx3複合体を含む組成物およびその使用方法 |
EP2900674B1 (en) | 2012-09-28 | 2017-05-31 | University of Washington through its Center for Commercialization | Compounds and methods for preventing, treating and/or protecting against sensory hair cell death |
US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
AU2013346501B2 (en) | 2012-11-19 | 2017-07-13 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of CETP inhibitors |
WO2014128564A2 (en) | 2013-02-21 | 2014-08-28 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of cetp inhibitors |
SG11201507093WA (en) | 2013-03-14 | 2015-10-29 | Univ Maryland Baltimore Office Of Technology Transfer | Androgen receptor down-regulating agents and uses thereof |
RU2016104643A (ru) | 2013-08-12 | 2017-09-19 | Токай Фармасьютикалз, Инк. | Биомаркёры для лечения неопластических заболеваний с применением нацеленных на андроген методов лечения |
EP2837391B1 (en) | 2013-08-12 | 2017-05-10 | Shin-Etsu Chemical Co., Ltd. | Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate |
US9296882B2 (en) | 2013-09-04 | 2016-03-29 | Zzyzx Polymers LLC | Methods for increasing throughput rates of solid-state extrusion devices |
WO2015054283A1 (en) | 2013-10-08 | 2015-04-16 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US20150104508A1 (en) * | 2013-10-12 | 2015-04-16 | Zzyzx Polymers LLC | Devices, compositions, and methods for fabricating drug delivery systems |
WO2015084998A1 (en) | 2013-12-05 | 2015-06-11 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
SI3104853T1 (sl) | 2014-02-10 | 2020-03-31 | Respivant Sciences Gmbh | Zdravljenje s stabilizatorji mastocitov za sistemske motnje |
US20150224078A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Methods for the Treatment of Lung Diseases with Mast Cell Stabilizers |
AP2016009407A0 (en) | 2014-03-17 | 2016-08-31 | Pfizer | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders |
US10231929B2 (en) | 2014-03-18 | 2019-03-19 | Takeda Pharmaceutical Company Limited | Solid dispersion |
WO2015164213A1 (en) | 2014-04-23 | 2015-10-29 | The Research Foundation For The State University Of New York | A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith |
TW201603818A (zh) | 2014-06-03 | 2016-02-01 | 組織科技股份有限公司 | 組成物及方法 |
US9839644B2 (en) | 2014-09-09 | 2017-12-12 | ARKAY Therapeutics, LLC | Formulations and methods for treatment of metabolic syndrome |
WO2016044733A1 (en) * | 2014-09-19 | 2016-03-24 | Board Of Regents, The University Of Texas System | Methods of preparing extrudates |
US9359316B1 (en) | 2014-11-25 | 2016-06-07 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
CN107438613B (zh) | 2015-02-06 | 2020-08-25 | 华盛顿大学 | 用于预防或治疗感觉毛细胞死亡的化合物和方法 |
US10227333B2 (en) | 2015-02-11 | 2019-03-12 | Curtana Pharmaceuticals, Inc. | Inhibition of OLIG2 activity |
WO2016138025A2 (en) | 2015-02-23 | 2016-09-01 | Tissuetech, Inc. | Apparatuses and methods for treating ophthalmic diseases and disorders |
JP2018510138A (ja) | 2015-02-27 | 2018-04-12 | カーテナ ファーマシューティカルズ,インク. | Olig2活性の阻害 |
BR122023020985A2 (pt) | 2015-03-03 | 2023-12-26 | Pharmacyclics Llc | Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton |
MA41827A (fr) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton |
MA41828A (fr) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton |
CN113413387A (zh) | 2015-05-11 | 2021-09-21 | H.隆德贝克有限公司 | 治疗炎症或神经性疼痛的方法 |
CN107847526A (zh) | 2015-05-20 | 2018-03-27 | 组织技术公司 | 用于预防上皮细胞的增殖和上皮‑间充质转换的组合物和方法 |
KR101994129B1 (ko) | 2015-05-28 | 2019-06-28 | 닥터 레디스 레보러터리즈 리미티드 | 통증 치료를 위한 셀레콕시브 경구용 조성물 |
WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
BR112018003836A2 (pt) | 2015-08-31 | 2018-12-04 | Pharmacyclics Llc | combinações de inibidor de btk para tratar mieloma múltiplo |
US10975149B2 (en) | 2015-12-16 | 2021-04-13 | The Walter And Eliza Hall Institute Of Medical Research | Inhibition of cytokine-induced SH2 protein in NK cells |
CN114681462A (zh) | 2016-01-19 | 2022-07-01 | 詹森药业有限公司 | 包含btk抑制剂的配制品/组合物 |
AU2017208472B2 (en) | 2016-01-19 | 2022-09-01 | Janssen Pharmaceutica Nv | Formulations/compositions comprising a BTK inhibitor |
TW201733600A (zh) | 2016-01-29 | 2017-10-01 | 帝聖工業公司 | 胎兒扶持組織物及使用方法 |
WO2017147146A1 (en) | 2016-02-23 | 2017-08-31 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists |
EP3442538A4 (en) | 2016-04-04 | 2019-11-20 | Sinopia Biosciences, Inc. | TREATMENT OF EXTRAPYRAMIDAL SYNDROME WITH TRAPIDILE |
ES2910787T3 (es) | 2016-05-12 | 2022-05-13 | Univ Michigan Regents | Inhibidores de ASH1L y métodos de tratamiento con los mismos |
KR102388870B1 (ko) | 2016-05-13 | 2022-04-20 | 메르크 파텐트 게엠베하 | 가소제로서의 아미노 당의 용도 |
US10821105B2 (en) | 2016-05-25 | 2020-11-03 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia |
WO2017205762A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
WO2017205766A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
WO2017205769A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
AU2017290593A1 (en) | 2016-06-27 | 2019-01-03 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
JP2019524747A (ja) | 2016-07-18 | 2019-09-05 | アースローシ セラピューティクス,インク. | 痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法 |
JP2019527693A (ja) | 2016-08-03 | 2019-10-03 | サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. | 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物 |
AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
JP7028860B2 (ja) | 2016-08-26 | 2022-03-02 | カーテナ ファーマシューティカルズ,インク. | Olig2活性の阻害 |
CA3035528A1 (en) | 2016-08-31 | 2018-03-08 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
EP3522983A4 (en) | 2016-10-07 | 2020-06-03 | Respivant Sciences GmbH | CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS |
WO2018083285A1 (en) | 2016-11-07 | 2018-05-11 | Merck Patent Gmbh | Controlled release tablet based on polyvinyl alcohol and its manufacturing |
MX2019005304A (es) | 2016-11-07 | 2019-08-12 | Merck Patent Gmbh | Pastilla de liberacion no abrupta de una dosis inducida por alcohol basada en alcohol polivinilico. |
KR20190083653A (ko) | 2016-11-07 | 2019-07-12 | 메르크 파텐트 게엠베하 | 고온 용융 압출된 폴리비닐 알코올에 기반하는 즉각 방출 캡슐 |
MA46867A (fr) | 2016-11-16 | 2019-09-25 | Abide Therapeutics Inc | Formulations pharmaceutiques |
LT3541807T (lt) | 2016-11-16 | 2021-12-27 | H. Lundbeck A/S | Magl inhibitoriaus kristalinė forma |
MX2019010756A (es) | 2017-03-10 | 2020-01-20 | Pfizer | Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2). |
CN115093337A (zh) * | 2017-08-01 | 2022-09-23 | 浙江普利药业有限公司 | 一种马来酸曲美布汀晶型及其制备方法 |
EP3675865A4 (en) | 2017-09-01 | 2021-06-02 | University of Washington | CRYSTALLINE FORMS OF COMPOUNDS TO PREVENT OR TREAT DEATH OF SENSORY CILIA CELLS |
WO2019094434A1 (en) | 2017-11-07 | 2019-05-16 | The Regents Of The University Of Michigan | Therapeutic combination for treatment of cerebellar ataxia |
WO2019094773A1 (en) | 2017-11-10 | 2019-05-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
CN112040947A (zh) | 2017-12-07 | 2020-12-04 | 密歇根大学董事会 | Nsd家族抑制剂及用其进行治疗的方法 |
US11685722B2 (en) | 2018-02-28 | 2023-06-27 | Curtana Pharmaceuticals, Inc. | Inhibition of Olig2 activity |
US11319302B2 (en) | 2018-06-07 | 2022-05-03 | The Regents Of The University Of Michigan | PRC1 inhibitors and methods of treatment therewith |
WO2020023794A1 (en) | 2018-07-27 | 2020-01-30 | Concentric Analgesics, Inc. | Pegylated prodrugs of phenolic trpv1 agonists |
JP2021535112A (ja) | 2018-08-20 | 2021-12-16 | アキリオン ファーマシューティカルズ,インコーポレーテッド | 補体d因子の医学的障害の治療のための医薬化合物 |
US20200069742A1 (en) | 2018-08-29 | 2020-03-05 | Myos Rens Technology Inc. | Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals |
MX2021002428A (es) | 2018-08-31 | 2023-01-02 | Pfizer | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas. |
US20200108102A1 (en) | 2018-10-03 | 2020-04-09 | Myos Rens Technology Inc. | Spray dried follistatin product |
EP3866773A4 (en) | 2018-10-16 | 2022-10-26 | Georgia State University Research Foundation, Inc. | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL CONDITIONS |
WO2020096660A1 (en) | 2018-11-06 | 2020-05-14 | Myos Rens Technology, Inc. | Methods and compositions for improving skeletal muscle protein fractional synthetic rate |
MX2021007925A (es) | 2018-12-31 | 2021-10-26 | Biomea Fusion Llc | Inhibidores irreversibles de la interaccion menina-mll. |
US11833186B2 (en) | 2019-02-01 | 2023-12-05 | Myos Corp. | Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals |
WO2020190890A1 (en) | 2019-03-15 | 2020-09-24 | Unicycive Therapeutics Inc. | Nicorandil derivatives |
WO2020210205A1 (en) * | 2019-04-08 | 2020-10-15 | Cosci Med-Tech Co., Ltd | Methods of improving pharmaceutical substance solubilization and products thereof |
WO2020212865A1 (en) | 2019-04-19 | 2020-10-22 | Pfizer Inc. | Anti-proliferative agents for treating pah |
CA3140972A1 (en) | 2019-05-20 | 2020-11-26 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
WO2020261144A1 (en) | 2019-06-28 | 2020-12-30 | Pfizer Inc. | 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases |
TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶2 抑制劑 |
JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
JP2021134211A (ja) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Nafld/nashおよび関連疾患の処置のための組合せ |
CA3175210A1 (en) | 2020-04-21 | 2021-10-28 | Cheryl A. Grice | Synthesis of a monoacylglycerol lipase inhibitor |
CR20220632A (es) | 2020-06-09 | 2023-01-23 | Pfizer | Antagonistas del receptor de melanocortina 4 y usos de estos |
CN116113406A (zh) | 2020-07-10 | 2023-05-12 | 密歇根大学董事会 | Gas41抑制剂及其使用方法 |
CA3202151A1 (en) | 2020-12-16 | 2022-06-23 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin-mll interaction |
CA3204457A1 (en) | 2021-01-06 | 2022-07-14 | Ben SESSA | Mdma in the treatment of alcohol use disorder |
WO2022238507A1 (en) | 2021-05-11 | 2022-11-17 | Awakn Ls Europe Holdings Limited | Therapeutic aminoindane compounds and compositions |
CA3221280A1 (en) | 2021-06-03 | 2022-12-08 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and methods of their use |
WO2023018825A1 (en) | 2021-08-11 | 2023-02-16 | Biomea Fusion, Inc. | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
IL310717A (en) | 2021-08-20 | 2024-04-01 | Biomea Fusion Inc | Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT |
WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
WO2023039240A1 (en) | 2021-09-13 | 2023-03-16 | Biomea Fusion, Inc. | IRREVERSIBLE INHIBITORS OF KRas |
WO2023086341A1 (en) | 2021-11-09 | 2023-05-19 | Biomea Fusion, Inc. | Inhibitors of kras |
WO2023100061A1 (en) | 2021-12-01 | 2023-06-08 | Pfizer Inc. | 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure |
WO2023105387A1 (en) | 2021-12-06 | 2023-06-15 | Pfizer Inc. | Melanocortin 4 receptor antagonists and uses thereof |
US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
WO2023139163A1 (en) | 2022-01-19 | 2023-07-27 | Awakn Ls Europe Holdings Limited | 1,3-benzodioxole esters and their therapeutic use |
WO2023156565A1 (en) | 2022-02-16 | 2023-08-24 | Awakn Ls Europe Holdings Limited | Bridged ring compounds and their therapeutic use as cns agents |
WO2023235618A1 (en) | 2022-06-03 | 2023-12-07 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin |
WO2024011142A1 (en) | 2022-07-06 | 2024-01-11 | Oppilan Pharma Limited | Crystalline forms of an s1p receptor modulator |
WO2024075051A1 (en) | 2022-10-07 | 2024-04-11 | Pfizer Inc. | Hsd17b13 inhibitors and/or degraders |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5257315A (en) * | 1975-11-04 | 1977-05-11 | Sandoz Ag | Tablet for medical preparation |
JPH02223533A (ja) * | 1988-11-08 | 1990-09-05 | Takeda Chem Ind Ltd | 放出制御性マトリックス剤 |
JPH02223513A (ja) * | 1988-12-20 | 1990-09-05 | Gist Brocades Nv | 多粒放出制御経口用組成物のための顆粒 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1504553A (en) * | 1975-11-17 | 1978-03-22 | Sandoz Ltd | Tablet formulations |
US4230687A (en) * | 1978-05-30 | 1980-10-28 | Griffith Laboratories U.S.A., Inc. | Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices |
JPS5785316A (en) * | 1980-11-14 | 1982-05-28 | Kanebo Ltd | Preparation of easily absorbable nifedipine preparation |
JPS58109411A (ja) * | 1981-12-23 | 1983-06-29 | Shionogi & Co Ltd | ニフエジピン固型製剤組成物 |
JPS6240277A (ja) * | 1985-08-15 | 1987-02-21 | Ajinomoto Co Inc | 顆粒状食品の製造法 |
US4778676A (en) * | 1985-12-20 | 1988-10-18 | Warner-Lambert Company | Confectionery delivery system for actives |
DE3612211A1 (de) * | 1986-04-11 | 1987-10-15 | Basf Ag | Kontinuierliches verfahren zum tablettieren |
DE3612212A1 (de) * | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
US4760094A (en) * | 1986-10-21 | 1988-07-26 | American Home Products Corporation (Del.) | Spray dried acetaminophen |
US4842761A (en) * | 1988-03-23 | 1989-06-27 | International Flavors & Fragrances, Inc. | Compositions and methods for controlled release of fragrance-bearing substances |
DE3812567A1 (de) * | 1988-04-15 | 1989-10-26 | Basf Ag | Verfahren zur herstellung pharmazeutischer mischungen |
DE3827061C1 (ja) * | 1988-08-10 | 1990-02-15 | Deutsche Gelatine-Fabriken Stoess & Co Gmbh, 6930 Eberbach, De | |
DE3830353A1 (de) * | 1988-09-07 | 1990-03-15 | Basf Ag | Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen |
NZ231281A (en) * | 1988-11-08 | 1991-01-29 | Takeda Chemical Industries Ltd | Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol |
US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
FR2670398B1 (fr) * | 1990-12-14 | 1995-02-17 | Roquette Freres | Composition pulverulente directement compressible et procede d'obtention. |
DK0617612T3 (da) * | 1991-12-18 | 1998-04-14 | Warner Lambert Co | Fremgangsmåde til fremstilling af en fast dispersion |
DE69332291T2 (de) * | 1992-10-16 | 2003-07-31 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung von wachsmatrizes |
DE19509807A1 (de) * | 1995-03-21 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen |
DE69530670T2 (de) * | 1994-09-21 | 2004-03-18 | Kanegafuchi Kagaku Kogyo K.K. | Verfahren zur absorption von interleukine |
HN1998000115A (es) * | 1997-08-21 | 1999-06-02 | Warner Lambert Co | Formas de dosificación farmacéuticas sólidas |
US5954175A (en) * | 1997-09-02 | 1999-09-21 | Northrop Grumman Corporation | Modularized parallel drivetrain |
CA2273272C (en) * | 1997-10-07 | 2004-09-21 | Fuisz Technologies Ltd. | Immediate release drug delivery forms |
US6029764A (en) * | 1997-11-12 | 2000-02-29 | Case Corporation | Coordinated control of an active suspension system for a work vehicle |
ES2306646T3 (es) * | 1999-02-09 | 2008-11-16 | Pfizer Products Inc. | Composiciones de farmacos basicos con biodisponibilidad incrementada. |
DE60042352D1 (de) * | 1999-02-10 | 2009-07-23 | Pfizer Prod Inc | Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten |
ES2307482T3 (es) * | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
-
1992
- 1992-04-14 EP EP92907654A patent/EP0580860B2/en not_active Expired - Lifetime
- 1992-04-14 AU AU15372/92A patent/AU1537292A/en not_active Abandoned
- 1992-04-14 AT AT92907654T patent/ATE159426T1/de active
- 1992-04-14 KR KR1019930703143A patent/KR0182801B1/ko not_active IP Right Cessation
- 1992-04-14 DK DK92907654T patent/DK0580860T4/da active
- 1992-04-14 CA CA002108575A patent/CA2108575C/en not_active Expired - Lifetime
- 1992-04-14 ES ES92907654T patent/ES2111065T5/es not_active Expired - Lifetime
- 1992-04-14 WO PCT/JP1992/000470 patent/WO1992018106A1/ja active IP Right Grant
- 1992-04-14 DE DE69222847T patent/DE69222847T3/de not_active Expired - Lifetime
- 1992-04-14 JP JP4507772A patent/JP2527107B2/ja not_active Expired - Lifetime
-
1993
- 1993-12-23 US US08/129,133 patent/US5456923A/en not_active Expired - Lifetime
-
1998
- 1998-01-08 GR GR980400035T patent/GR3025864T3/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5257315A (en) * | 1975-11-04 | 1977-05-11 | Sandoz Ag | Tablet for medical preparation |
JPH02223533A (ja) * | 1988-11-08 | 1990-09-05 | Takeda Chem Ind Ltd | 放出制御性マトリックス剤 |
JPH02223513A (ja) * | 1988-12-20 | 1990-09-05 | Gist Brocades Nv | 多粒放出制御経口用組成物のための顆粒 |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0665009A4 (en) * | 1992-10-14 | 1996-02-28 | Nippon Shinyaku Co Ltd | PROCESS FOR DISLOCATION OF A CRYSTALLINE STATE. |
EP0665010A4 (en) * | 1992-10-16 | 1996-02-28 | Nippon Shinyaku Co Ltd | METHOD FOR PRODUCING WAX MATRICES. |
WO1995005809A1 (fr) * | 1993-08-20 | 1995-03-02 | Nippon Shinyaku Co., Ltd. | Preparation restant dans l'estomac, forme moulee gonflee, et procede de preparation |
EP0642786A1 (en) * | 1993-09-14 | 1995-03-15 | Euro-Celtique S.A. | Method for the manufacture of a laxative composition |
US5525355A (en) * | 1993-09-14 | 1996-06-11 | Euro-Celtique, S.A. | Laxative compositions |
EP0729748A4 (en) * | 1993-11-18 | 1997-09-10 | Nippon Shinyaku Co Ltd | METHOD FOR PRODUCING STABLE MEDICINAL PRODUCTS AND PHARMACEUTICAL PREPARATION |
US6462093B1 (en) | 1995-08-11 | 2002-10-08 | Nissan Chemical Industries, Ltd. | Method for converting sparingly water-soluble medical substance to amorphous state |
US6139872A (en) * | 1996-08-14 | 2000-10-31 | Henkel Corporation | Method of producing a vitamin product |
JP2003522097A (ja) * | 1998-02-16 | 2003-07-22 | フイズ インターナショナル リミテッド | 可溶化デリバリーシステムおよび製造方法 |
JP2000281561A (ja) * | 1999-03-26 | 2000-10-10 | Ajinomoto Co Inc | 新規溶媒法固体分散体製剤 |
JP2004505911A (ja) * | 2000-08-03 | 2004-02-26 | ファイザー・プロダクツ・インク | コレステリルエステル転移蛋白質阻害薬の医薬用組成物 |
JP2007314573A (ja) * | 2000-08-03 | 2007-12-06 | Pfizer Prod Inc | コレステリルエステル転移蛋白質阻害薬の医薬用組成物 |
JP4997683B2 (ja) * | 2000-09-25 | 2012-08-08 | 日本新薬株式会社 | 医薬固体分散体の製法 |
JP2005523895A (ja) * | 2002-02-01 | 2005-08-11 | ファイザー・プロダクツ・インク | コレステリルエステル輸送タンパク質阻害剤の固体非晶質分散物を含む医薬組成物 |
JP2009529516A (ja) * | 2006-03-10 | 2009-08-20 | アボット ゲーエムベーハー ウント コンパニー カーゲー | 活性成分の固体分散体を生産するためのプロセス |
US9414992B2 (en) | 2006-03-10 | 2016-08-16 | Abbvie Deutschland Gmbh & Co Kg | Process for producing a solid dispersion of an active ingredient |
JP2009533320A (ja) * | 2006-03-10 | 2009-09-17 | アボット ゲーエムベーハー ウント コンパニー カーゲー | 活性成分の固体分散体を生産するための改良プロセス |
JP2015038115A (ja) * | 2006-03-10 | 2015-02-26 | アボット ゲーエムベーハー ウント コンパニー カーゲー | 活性成分の固体分散体を生産するための改良プロセス |
US9205027B2 (en) | 2006-03-10 | 2015-12-08 | Abbvie Deutschland Gmbh & Co Kg | Process for producing a solid dispersion of an active ingredient |
JPWO2009038112A1 (ja) * | 2007-09-21 | 2011-01-06 | 塩野義製薬株式会社 | Npyy5受容体拮抗剤を含有する固形製剤 |
WO2009038112A1 (ja) * | 2007-09-21 | 2009-03-26 | Shionogi & Co., Ltd. | Npyy5受容体拮抗剤を含有する固形製剤 |
WO2014073889A1 (en) * | 2012-11-07 | 2014-05-15 | Sk Biopharmaceuticals Co., Ltd. | Solid dispersions of insoluble drug and preparation method thereof |
US9439970B2 (en) | 2012-11-07 | 2016-09-13 | Sk Biopharmaceuticals Co., Ltd. | Solid dispersions of insoluble drug and preparation method thereof |
US9566268B2 (en) | 2012-11-07 | 2017-02-14 | Sk Biopharmaceuticals Co., Ltd. | Solid dispersions of insoluble drug and preparation method thereof |
US9724335B2 (en) | 2012-11-07 | 2017-08-08 | Sk Biopharmaceuticals Co., Ltd. | Solid dispersions of insoluble drug and preparation method thereof |
RU2646491C2 (ru) * | 2012-11-07 | 2018-03-05 | ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Твердые дисперсии нерастворимого лекарственного средства и способы их приготовления |
US9669047B2 (en) | 2012-12-27 | 2017-06-06 | Kao Corporation | Method for producing polyphenol composition |
US10894058B2 (en) | 2014-08-29 | 2021-01-19 | Kao Corporation | Method for producing solid dispersion containing hardly soluble polyphenol |
JP7082067B2 (ja) | 2016-05-13 | 2022-06-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 溶融押出用途のためのポリマーの粒子サイズおよび分布 |
Also Published As
Publication number | Publication date |
---|---|
CA2108575A1 (en) | 1992-10-17 |
DK0580860T4 (da) | 2005-03-21 |
DE69222847T3 (de) | 2005-09-15 |
DE69222847T2 (de) | 1998-05-20 |
EP0580860B2 (en) | 2004-12-15 |
EP0580860A4 (en) | 1994-06-15 |
US5456923A (en) | 1995-10-10 |
ATE159426T1 (de) | 1997-11-15 |
EP0580860B1 (en) | 1997-10-22 |
ES2111065T5 (es) | 2005-06-16 |
KR0182801B1 (ko) | 1999-05-01 |
DE69222847D1 (de) | 1997-11-27 |
GR3025864T3 (en) | 1998-04-30 |
DK0580860T3 (da) | 1998-05-25 |
CA2108575C (en) | 2002-10-22 |
ES2111065T3 (es) | 1998-03-01 |
EP0580860A1 (en) | 1994-02-02 |
JP2527107B2 (ja) | 1996-08-21 |
AU1537292A (en) | 1992-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1992018106A1 (en) | Method of manufacturing solid dispersion | |
US4344934A (en) | Therapeutic compositions with enhanced bioavailability | |
CA2153856C (en) | Duloxetine enteric pellets | |
JP3447042B2 (ja) | 単一物質球形粒の製造方法 | |
JPS61100527A (ja) | フイルム形成性の医薬用被覆剤水性分散液およびその製造法 | |
Kalpana et al. | Solid Dispersion: Approaches, Technology involved, Unmet need & Challenges. | |
EP0012523B2 (en) | Therapeutic compositions with enhanced bioavailability and process for their preparation | |
JPS6229514A (ja) | 医薬活性物質の遅延放出形粒状物及びその製造方法 | |
JP2002521393A (ja) | 経口及び皮膚投与形用被覆剤及び結合剤 | |
JP2003522188A (ja) | 基体へ静電適用するための粉末材料及びその粉末材料の基体への静電適用 | |
JPH01165530A (ja) | 被覆薬剤の製造方法 | |
WO2006131806A2 (en) | Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release | |
CA1110166A (en) | Coating ensuring a controlled release of active ingred ients of biologically active compositions, particularl y pharmaceutical compositions and a process for the pr eparation of biologically active compositions ensuring controlled release of active ingredients | |
CN102949359B (zh) | 一种头孢妥仑匹酯片及其制备方法 | |
WO1994008561A1 (en) | Crystalline condition dislocating method | |
CN108078934B (zh) | 一种盐酸齐拉西酮固体分散片及其热熔挤出方法 | |
US10668156B2 (en) | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers | |
WO2012098499A1 (en) | Solid molecular dispersion | |
Kukkar et al. | Mixing and formulation of low dose drugs: underlying problems and solutions | |
JPH11246404A (ja) | 吸収を改善した医薬組成物 | |
JPH09132522A (ja) | 発泡性組成物およびその製造方法 | |
WO2008013197A1 (en) | Spherical crude granule and method for production thereof | |
JP3910939B2 (ja) | 単一物質球形粒、それらを用いた食品、医薬及びそれらの製法 | |
BR112012006067B1 (pt) | Preparações de ingredientes ativos fracamente solúveis em água, processo para a produção de preparações,e, formas de dosagem | |
EP0347461B1 (en) | A sustained-release solid medicament form and a method for the preparation therefof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA FI HU JP KR NO RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2108575 Country of ref document: CA Ref document number: 1019930703143 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992907654 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08129133 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1992907654 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992907654 Country of ref document: EP |